Somewhat Favorable Press Coverage Somewhat Unlikely to Affect ArQule (ARQL) Share Price
Media coverage about ArQule (NASDAQ:ARQL) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ArQule earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 48.0861303305722 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Edited Transcript of ARQL earnings conference call or presentation 9-Nov-17 2:00pm GMT (finance.yahoo.com)
- ArQule, Inc. (ARQL) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS (americanbankingnews.com)
- FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome (drugs.com)
- Cancer Immunotherapy Technology Projected to Create Further Growth (bizjournals.com)
- EARNINGS SUMMARY: Details of ArQule Inc. Q3 Earnings Report (markets.businessinsider.com)
A number of analysts have issued reports on the stock. Zacks Investment Research cut shares of ArQule from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. ValuEngine cut shares of ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
ArQule (ARQL) traded up $0.09 during midday trading on Tuesday, reaching $1.30. 1,085,600 shares of the company’s stock were exchanged, compared to its average volume of 190,143. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 2.33. ArQule has a 1 year low of $0.92 and a 1 year high of $1.68.
ArQule (NASDAQ:ARQL) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.02. During the same quarter last year, the firm earned ($0.08) earnings per share. analysts anticipate that ArQule will post -0.39 EPS for the current fiscal year.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.